PRE-LAUNCH WHITE PAPER:
CFTR 100+ Panel: Built for evolving research.
122 variants. One panel. Confident CFTR detection.
Cystic fibrosis is one of the most studied inherited conditions, yet research often focuses on only the most common variants—leaving important insights underexplored.
In 2023, the American College of Medical Genetics and Genomics (ACMG) recommended 100 CFTR variants for carrier screening studies. But growing evidence, along with direct feedback from researchers, supports expanding beyond this list to capture less common and emerging variants that reflect diverse populations and changing research priorities.
The CFTR 100+ Panel (RUO) delivers all 100 ACMG-recommended variants plus additional variants of interest in a streamlined MassARRAY® System workflow. Using familiar iPLEX® chemistry, the panel helps minimize reruns, reduce ambiguous calls, and scale from a few to thousands of samples—all without complex bioinformatics.
This pre-launch whitepaper will allow you to:
-
See the complete list of variants: Review ACMG-recommended plus additional researcher-identified targets for expanded coverage.
-
Understand the workflow before you invest: Explore how multiplex PCR, SAP cleanup, and single-base extension integrate with MALDI-TOF mass spectrometry on the MassARRAY System.
-
Access trusted reference materials: Learn which CDC GeT-RM characterized DNA samples and commercially available controls can support your evaluation and validation
The follow-up technical white paper will show how the panel performs in real-world labs, giving early adopters the insight they need to move confidently.
By completing the form you will also get:
- Early access to the full technical white paper
- Forthcoming real-world performance insights
Download Now
Complete the form to receive this exclusive white paper.